subscribeSubscribe
CD38/48 Upregulation With Tazemetostat May Overcome Daratumumab Resistance

CD38/48 Upregulation With Tazemetostat May Overcome Daratumumab Resistance
ONCLIVE
29 Sep 2023
Share Share
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat
GLOBENEWSWIRE
11 Sep 2023
Share Share
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology

Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
PRESS RELEASE
13 Aug 2022
Share Share
Epizyme Reports Second Quarter 2022 Financial Results

Epizyme Reports Second Quarter 2022 Financial Results
BUSINESSWIRE
09 Aug 2022
Share Share
Hutchmed begins dosing in follicular lymphoma therapy trial in China

Hutchmed begins dosing in follicular lymphoma therapy trial in China
CLINICALTRIALSARENA
01 Aug 2022
Share Share
Ipsen snaps up Epizyme and cancer drug Tazverik for $247M

Ipsen snaps up Epizyme and cancer drug Tazverik for $247M
Kevin Deunleavy FIERCEPHARMA
28 Jun 2022
Share Share
HUTCHMED Announces TAZVERIK Approved to be Used in Hainan Pilot Zone in China

HUTCHMED Announces TAZVERIK Approved to be Used in Hainan Pilot Zone in China
GLOBENEWSWIRE
01 Jun 2022
Share Share
Epizyme to trim workforce and pipeline in cost-cutting plan

Epizyme to trim workforce and pipeline in cost-cutting plan
Max Bayer FIERCEBIOTECH
02 Mar 2022
Share Share
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study
BUSINESSWIRE
12 Dec 2021
Share Share
Epizyme Reports Q3 2021 Financial Results and Provides Business Update

Epizyme Reports Q3 2021 Financial Results and Provides Business Update
BUSINESSWIRE
09 Nov 2021
Share Share